| |
Number of patients (%)
|
|---|
|
Adverse event (preferred term)
|
Placebo (n = 16)
|
IFN beta-1a 44 mcg biw (n = 17)
|
IFN beta-1a 44 mcg tiw (n = 16)
|
IFN beta-1a 66 mcg tiw (n = 18)
|
Total (n = 67)
|
|---|
|
Influenza-like symptoms
|
3 (18.8)
|
8 (47.1)
|
6 (37.5)
|
7 (38.9)
|
24 (35.8)
|
|
Headache
|
3 (18.8)
|
8 (47.1)
|
7 (43.8)
|
4 (22.2)
|
22 (32.8)
|
|
Injection-site reaction
|
2 (12.5)
|
5 (29.4)
|
6 (37.5)
|
5 (27.8)
|
18 (26.9)
|
|
Fever
|
2 (12.5)
|
3 (17.6)
|
5 (31.3)
|
6 (33.3)
|
16 (23.9)
|
|
Abdominal pain
|
4 (25.0)
|
2 (11.8)
|
5 (31.3)
|
5 (27.8)
|
16 (23.9)
|
|
Injection-site inflammation
|
2 (12.5)
|
3 (17.6)
|
5 (31.3)
|
5 (27.8)
|
15 (22.4)
|
|
Fatigue
|
3 (18.8)
|
3 (17.6)
|
4 (25.0)
|
2 (11.1)
|
12 (17.9)
|
|
Nausea
|
3 (18.8)
|
3 (17.6)
|
2 (12.5)
|
3 (16.7)
|
11 (16.4)
|
|
ESR increased
|
0
|
2 (11.8)
|
5 (31.3)
|
3 (16.7)
|
10 (14.9)
|
|
Arthralgia
|
2 (12.5)
|
4 (23.5)
|
3 (18.8)
|
1 (5.6)
|
10 (14.9)
|
|
Injection-site rash
|
0
|
3 (17.6)
|
3 (18.8)
|
2 (11.1)
|
8 (11.9)
|
|
Rhinitis
|
2 (12.5)
|
2 (11.8)
|
3 (18.8)
|
1 (5.6)_
|
8 (11.9)
|
|
Myalgia
|
1 (6.3)
|
4 (23.5)
|
2 (12.5)
|
1 (5.6)
|
8 (11.9)
|
|
Injection-site pain
|
0
|
2 (11.8)
|
1 (6.3)
|
4 (22.2)
|
7 (10.4)
|
|
Anaemia
|
0
|
4 (23.5)
|
2 (12.5)
|
1 (5.6)
|
7 (10.4)
|
- biw: twice weekly; ESR: erythrocyte sedimentation rate; IFN: interferon; tiw: three times weekly
